Levosimendan Farmak (Levosimendan)

Levosimendan works by sensitizing cardiac troponin C to calcium, which strengthens the interaction between actin and myosin without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and lowering after‑load, together improving cardiac performance.

The dosing regimen for Levosimendan Farmak is determined by the prescribing clinician based on the patient’s clinical status, weight, and response. It is administered intravenously, typically as a loading dose followed by a continuous infusion, with adjustments made according to hemodynamic monitoring.

Safety data for levosimendan during pregnancy and lactation are limited. It should only be used when the potential maternal benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Levosimendan differs from traditional inotropes such as dobutamine by increasing contractility without raising intracellular calcium, which may reduce the risk of arrhythmias. Additionally, its vasodilatory action lowers after‑load, whereas dobutamine primarily raises heart rate and contractility with less vasodilation.

Levosimendan Farmak should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen. The product should be kept in its original packaging to maintain stability and prevent contamination.

Levosimendan is given by intravenous infusion. A typical protocol includes a short loading dose followed by a continuous infusion over several hours, with continuous monitoring of blood pressure, heart rate, and cardiac output to guide therapy.

The most serious adverse events include severe hypotension, life‑threatening arrhythmias, myocardial ischemia, and allergic reactions such as anaphylaxis. Prompt recognition and management of these events are essential during therapy.

Levosimendan is contraindicated in patients with severe hypotension, obstructive cardiomyopathy, significant ventricular outflow obstruction, or known hypersensitivity to the drug. Caution is also advised in individuals with severe renal or hepatic impairment.